Post by Chris Dokomajilar

Global Healthcare and Life Sciences dealmaking remained resilient in H1 2026 despite a more selective capital deployment environment in Q2. R&D partnerships generated 327 deals worth $172.6B with $9.4B in upfront cash and equity. Although deal volume moderated, the quarter was highlighted by Bristol Myers Squibb’s potential $15.2B collaboration with Hengrui Pharma across oncology, hematology, and immunology, Pfizer’s up to $10.5B oncology alliance with Innovent Biologics focused on ADCs and multispecific antibodies, and Fosun Pharma USA Inc.’s up to $4.7B option agreement for AriBio’s Phase III Alzheimer’s disease candidate AR1001. M&A activity reached 305 transactions totaling $194.1B, including contingents, led by SUN PHARMA’s $11.8B acquisition of Organon to strengthen its women’s health and biosimilars business, Merck’s $11.3B acquisition of Bio-Techne to expand its life sciences tools and diagnostics capabilities, and AbbVie’s $10.9B acquisition of Apogee Therapeutics to reinforce its immunology and respiratory pipeline. Read the rest of the research https://lnkd.in/gzWCtqHR